← All trials
NCT05676203
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 16, 2023
- Primary completion
- Feb 28, 2025
- Completion date
- Aug 31, 2026
- First posted
- Jan 9, 2023
- Last posted
- Jul 21, 2023
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Friedrich Schiller UniversityLead sponsor
- BayerCollaborator
- Friedrich Schiller UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.